Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Trial details
- Registry ID
- NCT06106308
- Drugs studied
- Bevacizumab, FOLFIRI, FOLFOX, Onvansertib